Pfizer Inc (PFE)
25.13
+0.19
(+0.76%)
USD |
NYSE |
Nov 21, 16:00
25.08
-0.05
(-0.20%)
Pre-Market: 06:16
Pfizer Research and Development Expense (Quarterly): 2.598B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.598B |
| June 30, 2024 | 2.696B |
| March 31, 2024 | 2.493B |
| December 31, 2023 | 2.815B |
| September 30, 2023 | 2.711B |
| June 30, 2023 | 2.648B |
| March 31, 2023 | 2.505B |
| December 31, 2022 | 3.615B |
| September 30, 2022 | 2.696B |
| June 30, 2022 | 2.815B |
| March 31, 2022 | 2.301B |
| December 31, 2021 | 3.446B |
| September 30, 2021 | 2.681B |
| June 30, 2021 | 2.239B |
| March 31, 2021 | 1.994B |
| December 31, 2020 | 3.343B |
| September 30, 2020 | 2.30B |
| June 30, 2020 | 2.078B |
| March 31, 2020 | 1.672B |
| December 31, 2019 | 2.558B |
| September 30, 2019 | 2.283B |
| June 30, 2019 | 1.842B |
| March 31, 2019 | 1.703B |
| December 31, 2018 | 2.211B |
| September 30, 2018 | 2.008B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.797B |
| March 31, 2018 | 1.743B |
| December 31, 2017 | 2.316B |
| September 30, 2017 | 1.865B |
| June 30, 2017 | 1.787B |
| March 31, 2017 | 1.716B |
| December 31, 2016 | 2.532B |
| September 30, 2016 | 1.881B |
| June 30, 2016 | 1.748B |
| March 31, 2016 | 1.731B |
| December 31, 2015 | 2.348B |
| September 30, 2015 | 1.722B |
| June 30, 2015 | 1.734B |
| March 31, 2015 | 1.885B |
| December 31, 2014 | 3.209B |
| September 30, 2014 | 1.802B |
| June 30, 2014 | 1.759B |
| March 31, 2014 | 1.623B |
| December 31, 2013 | 1.811B |
| September 30, 2013 | 1.627B |
| June 30, 2013 | 1.53B |
| March 31, 2013 | 1.71B |
| December 31, 2012 | 2.021B |
| September 30, 2012 | 1.887B |
| June 30, 2012 | 1.60B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.672B
Minimum
Mar 2020
3.615B
Maximum
Dec 2022
2.610B
Average
2.623B
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Johnson & Johnson | 4.952B |
| Eli Lilly and Co | 2.734B |
| Merck & Co Inc | 5.862B |
| Moderna Inc | 1.137B |